U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from Books

Items: 19

1.
Mycophenolate mofetil for immune checkpoint inhibitor‐related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review
Masayuki Ueno, Hiroyuki Takabatake, Ayako Hata, Takahisa Kayahara, Youichi Morimoto, Kenji Notohara, Motowo Mizuno
Cancer Rep (Hoboken) 2022 Sep; 5(9): e1624. Published online 2022 May 16. doi: 10.1002/cnr2.1624
PMCID:
PMC9458512
AbstractArticlePDF–2.0M
2.
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
David R. Spigel, Corinne Faivre-Finn, Jhanelle E. Gray, David Vicente, David Planchard, Luis Paz-Ares, Johan F. Vansteenkiste, Marina C. Garassino, Rina Hui, Xavier Quantin, Andreas Rimner, Yi-Long Wu, Mustafa Özgüroğlu, Ki H. Lee, Terufumi Kato, Maike de Wit, Takayasu Kurata, Martin Reck, Byoung C. Cho, Suresh Senan, Jarushka Naidoo, Helen Mann, Michael Newton, Piruntha Thiyagarajah, Scott J. Antonia
J Clin Oncol. 2022 Apr 20; 40(12): 1301–1311. Published online 2022 Feb 2. doi: 10.1200/JCO.21.01308
PMCID:
PMC9015199
AbstractArticlePDF–1.0M
3.
Durvalumab, tremelimumab alone or in combination with low-dose or hypofractionated targeted radiotherapy in metastatic non-small cell lung cancer refractory to prior PD(L)-1 therapy: a multicentre, open-label, randomised, phase 2 trial
Jonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, Katrina Z Kao, Ana Lako, Junko Tsuji, Yang Liu, Ryan C Brennick, Ryan D Gentzler, Carrie Lee, Joleen Hubbard, Susanne M Arnold, James L Abbruzzese, Salma K Jabbour, Nataliya V Uboha, Kevin L Stephans, Jennifer M Johnson, Haeseong Park, Liza C Villaruz, Elad Sharon, Howard Streicher, Mansoor M Ahmed, Hayley Lyon, Carrie Cibuskis, Niall Lennon, Aashna Jhaveri, Lin Yang, Jennifer Altreuter, Lauren Gunasti, Jason L Weirather, Raymond H Mak, Mark M Awad, Scott J Rodig, Helen X Chen, Catherine J Wu, Arta M Monjazeb, F Stephen Hodi
Lancet Oncol. Author manuscript; available in PMC 2023 Feb 1.
Published in final edited form as: Lancet Oncol. 2022 Feb; 23(2): 279–291. Published online 2022 Jan 13. doi: 10.1016/S1470-2045(21)00658-6
PMCID:
PMC8813905
AbstractArticlePDF–741K
4.
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
Patrick M. Forde, Valsamo Anagnostou, Zhuoxin Sun, Suzanne E. Dahlberg, Hedy L. Kindler, Noushin Niknafs, Thomas Purcell, Rafael Santana-Davila, Arkadiusz Z. Dudek, Hossein Borghaei, Mara Lanis, Zineb Belcaid, Kellie N. Smith, Archana Balan, James R. White, Christopher Cherry, I. K. Ashok Sivakumar, Xiaoshan M. Shao, Hok Yee Chan, Dipika Singh, Sampriti Thapa, Peter B. Illei, Drew M. Pardoll, Rachel Karchin, Victor E. Velculescu, Julie R. Brahmer, Suresh S. Ramalingam
Nat Med. 2021; 27(11): 1910–1920. Published online 2021 Nov 8. doi: 10.1038/s41591-021-01541-0
PMCID:
PMC8604731
AbstractArticlePDF–10M
5.
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum‐Based Chemotherapy in Extensive Stage Small Cell Lung Cancer
Luckson Mathieu, Sujay Shah, Lee Pai‐Scherf, Erin Larkins, Jonathon Vallejo, Xiaoxue Li, Lisa Rodriguez, Pallavi Mishra‐Kalyani, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Julia A. Beaver, Richard Pazdur, Harpreet Singh
Oncologist. 2021 May; 26(5): 433–438. Published online 2021 Mar 25. doi: 10.1002/onco.13752
PMCID:
PMC8100557
AbstractArticlePDF–370K
6.
Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab
Koki Nakashima, Yoshiki Demura, Masahiro Oi, Mio Tabata, Toshihiko Tada, Kohei Shiozaki, Masaya Akai, Tamotsu Ishizuka
Intern Med. 2020 Dec 1; 59(23): 3055–3059. Published online 2020 Jul 28. doi: 10.2169/internalmedicine.5216-20
PMCID:
PMC7759708
AbstractArticlePDF–506K
7.
Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer
Masakatsu Nakamura, Toshimi Otsuka, Ranji Hayashi, Tomoe Horita, Masafumi Ota, Naoko Sakurai, Hikaru Takano, Tasuku Hayashi, Motona Kumagai, Sohsuke Yamada, Tomiyasu Arisawa
Intern Med. 2020 Nov 1; 59(21): 2711–2717. Published online 2020 Jul 14. doi: 10.2169/internalmedicine.4699-20
PMCID:
PMC7691038
AbstractArticlePDF–910K
8.
Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
Rosanna Ruggiero, Federica Fraenza, Cristina Scavone, Gabriella di Mauro, Raffaele Piscitelli, Annamaria Mascolo, Carmen Ferrajolo, Concetta Rafaniello, Liberata Sportiello, Francesco Rossi, Annalisa Capuano
Front Pharmacol. 2020; 11: 830. Published online 2020 Jun 9. doi: 10.3389/fphar.2020.00830
PMCID:
PMC7295943
AbstractArticlePDF–1.0M
9.
Immunotherapy-related hepatitis: real-world experience from a tertiary centre
Vincent Cheung, Tarun Gupta, Miranda Payne, Mark R Middleton, Jane D Collier, Alison Simmons, Paul Klenerman, Oliver Brain, Jeremy F Cobbold
Frontline Gastroenterol. 2019 Oct; 10(4): 364–371. Published online 2019 Mar 22. doi: 10.1136/flgastro-2018-101146
PMCID:
PMC6788136
AbstractArticlePDF–770K
10.
Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment
Hamzah Abu-Sbeih, Cynthia Nguyen Tran, Phillip S. Ge, Manoop S. Bhutani, Mazen Alasadi, Aung Naing, Amir A. Jazaeri, Yinghong Wang
J Immunother Cancer. 2019; 7: 118. Published online 2019 May 3. doi: 10.1186/s40425-019-0604-2
PMCID:
PMC6499962
AbstractArticlePDF–717K
11.
Safety and Efficacy of Retreating with Immunotherapy After Immune-Related Adverse Events in Patients with NSCLC
Fernando C. Santini, Hira Rizvi, Andrew J. Plodkowski, Andy Ni, Mario E. Lacouture, Maya Gambarin-Gelwan, Olivia Wilkins, Elizabeth Panora, Darragh F. Halpenny, Niamh M. Long, Mark G. Kris, Charles M. Rudin, Jamie E. Chaft, Matthew D. Hellmann
Cancer Immunol Res. Author manuscript; available in PMC 2019 Sep 1.
Published in final edited form as: Cancer Immunol Res. 2018 Sep; 6(9): 1093–1099. Published online 2018 Jul 10. doi: 10.1158/2326-6066.CIR-17-0755
PMCID:
PMC6125223
AbstractArticlePDF–560K
12.
Durvalumab: First Global Approval
Yahiya Y. Syed
Drugs. 2017; 77(12): 1369–1376. Published online 2017 Jun 22. doi: 10.1007/s40265-017-0782-5
Correction in:
Drugs. 2017; 77(16): 1817.
PMCID:
PMC5636860
AbstractArticlePDF–514K
13.
Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard, Michael S. Gordon, Sunil Sharma, Saeed Rafii, Zev A. Wainberg, Jason Luke, Tyler J. Curiel, Gerardo Colon-Otero, Omid Hamid, Rachel E. Sanborn, Peter H. O’Donnell, Alexandra Drakaki, Winston Tan, John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. Blake-Haskins, Ashok Gupta, Neil H. Segal
J Clin Oncol. 2016 Sep 10; 34(26): 3119–3125. Published online 2016 Jun 6. doi: 10.1200/JCO.2016.67.9761
PMCID:
PMC5569690
AbstractArticlePDF–944K
14.
Safety and antitumour activity in a phase 1b study of combined checkpoint blockade with anti-PD-L1 (durvalumab) and anti-CTLA4 (tremelimumab) in non-small cell lung cancer
Scott Antonia, Sarah B. Goldberg, Ani Balmanoukian, Jamie E. Chaft, Rachel E. Sanborn, Ashok Gupta, Rajesh Narwal, Keith Steele, Yu Gu, Joyson Joseph Karakunnel, Naiyer A. Rizvi
Lancet Oncol. Author manuscript; available in PMC 2017 Jul 6.
Published in final edited form as: Lancet Oncol. 2016 Mar; 17(3): 299–308. Published online 2016 Feb 6. doi: 10.1016/S1470-2045(15)00544-6
PMCID:
PMC5500167
AbstractArticlePDF–424K
15.
PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
Diwakar Davar, Melissa Wilson, Chelsea Pruckner, John M. Kirkwood
Case Rep Oncol Med. 2015; 2015: 737389. Published online 2015 Sep 10. doi: 10.1155/2015/737389
PMCID:
PMC4581502
AbstractArticlePDF–1015K
16.
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley, I. Peter Shintaku, Emma J. M. Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu, Alisha N. West, Manuel Carmona, Christine Kivork, Elizabeth Seja, Grace Cherry, Antonio Gutierrez, Tristan R. Grogan, Christine Mateus, Gorana Tomasic, John A. Glaspy, Ryan O. Emerson, Harlan Robins, Robert H. Pierce, David A. Elashoff, Caroline Robert, Antoni Ribas
Nature. Author manuscript; available in PMC 2015 May 26.
Published in final edited form as: Nature. 2014 Nov 27; 515(7528): 568–571. doi: 10.1038/nature13954
PMCID:
PMC4246418
AbstractArticlePDF–4.2M
17.
Pathologic Changes in Ipilimumab-related Hepatitis in Patients with Metastatic Melanoma
David E. Kleiner, David Berman
Dig Dis Sci. Author manuscript; available in PMC 2013 Oct 8.
Published in final edited form as: Dig Dis Sci. 2012 Aug; 57(8): 2233–2240. Published online 2012 Mar 21. doi: 10.1007/s10620-012-2140-5
PMCID:
PMC3792485
AbstractArticlePDF–2.4M
18.
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott N. Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott J. Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure-Kunkel, Shruti Agrawal, Daniel McDonald, Georgia D. Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
N Engl J Med. Author manuscript; available in PMC 2013 Jan 14.
Published in final edited form as: N Engl J Med. 2012 Jun 28; 366(26): 2443–2454. Published online 2012 Jun 2. doi: 10.1056/NEJMoa1200690
PMCID:
PMC3544539
AbstractArticlePDF–1.5M
19.
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Giao Q. Phan, James C. Yang, Richard M. Sherry, Patrick Hwu, Suzanne L. Topalian, Douglas J. Schwartzentruber, Nicholas P. Restifo, Leah R. Haworth, Claudia A. Seipp, Linda J. Freezer, Kathleen E. Morton, Sharon A. Mavroukakis, Paul H. Duray, Seth M. Steinberg, James P. Allison, Thomas A. Davis, Steven A. Rosenberg
Proc Natl Acad Sci U S A. 2003 Jul 8; 100(14): 8372–8377. Published online 2003 Jun 25. doi: 10.1073/pnas.1533209100
PMCID:
PMC166236
AbstractArticlePDF–644K

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center